Cam­brex sells drug prod­uct busi­ness; Land­mark to work with Gala­pa­gos; Genezen locks $18.5M eq­ui­ty boost 

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

CD­MO Cam­brex sold its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.